Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18818638 | 1.00 | TLR7 (0.60) | TLR7 | |
| SCHEMBL18823839 | 0.99 | TLR7 (0.58) | TLR7 | |
| SCHEMBL18824091 | 0.98 | TLR7 (0.58) | TLR7 | |
| SCHEMBL18788786 | 0.95 | TLR7 (0.63) | TLR7 | |
| SCHEMBL28354637 | 0.94 | TLR7 (0.64) | TLR7 | |
| SCHEMBL18819121 | 0.94 | TLR7 (0.63) | TLR7 | |
| SCHEMBL18788767 | 0.93 | TLR7 (0.61) | TLR7 | |
| SCHEMBL18818931 | 0.93 | TLR7 (0.65) | TLR7 | |
| SCHEMBL18788805 | 0.93 | TLR7 (0.61) | TLR7 | |
| SCHEMBL22268895 | 0.93 | TLR7 (0.55) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346387-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2021-11-11 | — | — | US | disclosed |
| EP-3797797-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | Novartis AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| EP-3368092-B9 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2020-07-29 | — | — | EP | disclosed |
| US-20200164084-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346387-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR2, TLR9 | TLR7 6/4885 |
| US-20200164084-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES | TLR3, TLR2, TLR9 | TLR7 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.